Billionaire Cliff Asness’ Top 10 Healthcare Stock Picks
Cliff Asness is a billionaire investor and the co-founder and chief investment officer of AQR Capital Management, a quantitative hedge fund.
Exelixis Inc. (EXEL)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 13,726,993 | $588,750,730 | -2% | 0.92% |
| 2. | Farallon Capital Thomas Steyer | 13,111,010 | $562,331,219 | -17% | 3.21% |
| 3. | AQR Capital Management Cliff Asness | 13,095,741 | $561,676,342 | -5% | 0.26% |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 4,834,625 | $207,357,066 | -9% | 0.11% |
| 5. | D E Shaw D. E. Shaw | 3,603,063 | $154,535,372 | +94% | 0.09% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $43.12 | 27,532 | $1,187,234.90 | 1,553,262 | 2025-11-25 | Filing | |
| $20.76 | 225,000 | $4,670,055.00 | 1,525,730 | 2024-05-30 | Filing | |
| $20.32 | 200,000 | $4,063,900.00 | 1,300,730 | 2024-05-28 | Filing | |
| $20.70 | 190,000 | $3,932,734.00 | 1,100,730 | 2024-02-21 | Filing | |
| $21.61 | 120,409 | $2,602,038.49 | 910,730 | 2023-11-27 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $50.55 | 3,925 | $198,408.75 | 284,384 | 2026-06-01 | Filing | |
| $50.14 | 9,812 | $491,973.68 | 16,079 | 2026-06-01 | Filing | |
| $50.35 | 43,451 | $2,187,757.85 | 594,741 | 2026-05-26 | Filing | |
| $49.81 | 32,110 | $1,599,399.10 | 357,638 | 2026-05-20 | Filing | |
| $50.00 | 34,901 | $1,745,050.00 | 952,317 | 2026-05-18 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,288 | $124,490 | 0.01% | |
| 2. | 1,697 | $92,334 | 0% | |
| 3. | 1,029 | $57,238 | 0.03% | |
| 4. | 91,216 | $4,963 | 0.14% | |
| 5. | 46 | $2,503 | 0% |
News See All
12 Best Stocks to Invest In According to Jim Simons' Renaissance Technologies
Founded in 1982 by mathematician Jim Simons, Renaissance Technologies is widely regarded as the most successful quantitative hedge fund in financial history.
12 Best Low Priced Growth Stocks to Invest In Now
On May 13, Sébastien Page, T. Rowe Price Head of Global Multi-Asset & CIO, joined CNBC's 'Squawk Box' to discuss navigating a stock market hitting consecutive record highs.
TD Cowen Sees Pipeline Growth Opportunities Supporting Exelixis, Inc. (EXEL) Outlook
TheFly reported on May 6 that EXEL received an updated valuation outlook as TD Cowen increased its price target to $55 from $51 while reaffirming a Buy rating on the stock.
10 Best Cancer Stocks to Buy for the Long Term
Pharmaceutical firms have always had a special place in the healthcare market because they provide stability and expansion.
Exelixis, Inc. (NASDAQ:EXEL) Q1 2026 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the Exelixis, Inc. first quarter 2026 Financial Results Conference Call. My name is Sherry, and I will be your operator for today.
15 Set-It-and-Forget-It Stocks to Buy in 2026
Long-term wealth building requires choosing investments that could withstand various economic conditions.
Exelixis, Inc. (NASDAQ:EXEL) Q4 2025 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the Exelixis Fourth Quarter and Fiscal Year 2025 Financial Results Conference Call. My name is Towanda, and I will be your operator for today.
Why Exelixis (EXEL) is One of the Best Healthcare Stocks Under $50 to Invest In
Exelixis, Inc. (NASDAQ:EXEL) is one of the best healthcare stocks under $50 to invest in. On February 4, Barclays revised the price target on Exelixis, Inc.
12 Best Healthcare Stocks Under $50 to Invest In
On January 27, Jared Holz, healthcare equity strategist at Mizuho, appeared on CNBC’s 'Power Lunch' to talk about healthcare stocks and the new proposals around Medicare Advantage.
Hedge Fund Resource Center